Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs

Migraine is a common and disabling neurological disorder, with a significant socioeconomic burden. Its pathophysiology involves abnormalities in complex neuronal networks, interacting at different levels of the central and peripheral nervous system, resulting in the constellation of symptoms charact...

Full description

Saved in:
Bibliographic Details
Published in:Drugs (New York, N.Y.) N.Y.), 2018-03, Vol.78 (4), p.411-437
Main Authors: Ong, Jonathan Jia Yuan, Wei, Diana Yi-Ting, Goadsby, Peter J.
Format: Article
Language:English
Subjects:
Abnormalities
Antibodies, Monoclonal - therapeutic use
Botulinum toxin
Calcitonin
Calcitonin gene-related peptide
Calcitonin Gene-Related Peptide - metabolism
Constellations
Drug therapy
Headache
Headaches
Humans
Internal Medicine
Medicine
Medicine & Public Health
Migraine
Migraine Disorders - drug therapy
Migraine Disorders - physiopathology
Migraine Disorders - prevention & control
Molecular Targeted Therapy - methods
Nervous system
Neural networks
Neurobiology
Neurological disorders
Neurons - physiology
Neurosciences
Pain
Patients
Peripheral nervous system
Pharmacology
Pharmacology/Toxicology
Pharmacotherapy
Prevention
Receptors, Calcitonin Gene-Related Peptide - metabolism
Review Article
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Migraine is a common and disabling neurological disorder, with a significant socioeconomic burden. Its pathophysiology involves abnormalities in complex neuronal networks, interacting at different levels of the central and peripheral nervous system, resulting in the constellation of symptoms characteristic of a migraine attack. Management of migraine is individualised and often necessitates the commencement of preventive medication. Recent advancements in the understanding of the neurobiology of migraine have begun to account for some parts of the symptomatology, which has led to the development of novel target-based therapies that may revolutionise how migraine is treated in the future. This review will explore recent advances in the understanding of migraine pathophysiology, and pharmacotherapeutic developments for migraine prevention, with particular emphasis on novel treatments targeted at the calcitonin gene-related peptide (CGRP) pathway.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-018-0865-y